埃尔特罗姆博帕格
医学
耐火材料(行星科学)
抗胸腺细胞球蛋白
内科学
相伴的
胃肠病学
外科
不利影响
环孢素
血小板
化疗
移植
免疫性血小板减少症
天体生物学
物理
作者
Y. Hwang,Harinder Gill,Thomas Sau Yan Chan,Garret M. K. Leung,Carol Y M Cheung,Yok‐Lam Kwong
出处
期刊:Hematology
[Informa]
日期:2018-01-05
卷期号:23 (7): 399-404
被引量:30
标识
DOI:10.1080/10245332.2017.1422306
摘要
The thrombopoietin mimetic eltrombopag has been used in clinical trials for the frontline and salvage treatment of aplastic anaemia (AA). Eltrombopag was investigated in AA patients on a non-trial all-comer basis.Consecutive newly diagnosed and relapsed/refractory AA patients were treated with eltrombopag.In a 4.5-year period, 20 consecutive AA patients (newly diagnosed, N = 10; relapsed/refractory, N = 10) at a median age of 47 (22-84) years were treated with eltrombopag. For newly diagnosed patients, the frontline use of eltrombopag (concomitant medications: anti-thymocyte globulin, ATG, and ciclosporin, N = 4; ciclosporin, N = 5; nil, N = 1) at a median maximum dose of 150 (50-300) mg/day led to an overall response rate (ORR) of 90% (trilineage: 60%; neutrophil: 20%; platelet: 10%). After a median follow-up of 47 (14-179) weeks, responses were maintained in all cases. In relapsed/refractory patients, eltrombopag at a median maximum dose of 150 (50-300) mg/day led to an ORR of 50% (trilineage: 40%; neutrophil: 10%), with responses maintained after a median follow-up of 115 (53-253) weeks. Adverse effects included reversible skin pigmentation (observed in all patients taking eltrombopag at ≥150 mg/day), dyspepsia, and liver function derangement.In a routine haematological practice, the use of eltrombopag in AA patients was feasible, safe, and associated with very favourable responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI